Patents by Inventor Orlaith RYAN

Orlaith RYAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ORAL SUSPENSIONS COMPRISING TEMOZOLOMIDE OR LENALIDOMIDE
    Publication number: 20250017918
    Abstract: The present disclosure provides a composition comprising temozolomide or lenalidomide, a medium chain triglyceride such as miglyol, silicon dioxide and a surfactant, wherein the composition optionally comprises an antioxidant and/or a flavoring agent, and wherein the temozolomide composition is a non-aqueous, preservative free suspension. Also provided is a method for treating cancer in a subject, such as a child or a subject suffering dysphagia and/or has difficulty swallowing.
    Type: Application
    Filed: July 5, 2024
    Publication date: January 16, 2025
    Inventors: Sharon CUNNINGHAM, Orlaith RYAN, Denis DELANEY, Maurice CLANCY, Rod BAKER
  • Stable formulations comprising thiotepa
    Patent number: 11975013
    Abstract: The present disclosure provides pharmaceutical compositions comprising thiotepa and one selected from PEG, such as PEG400 or PEG600, and DMSO, and optionally water or an aqueous saline solution and thiosulfate. The composition is free or substantially free of impurities. Also provided is a method for treating cancer in a subject, or myeloablation prior to bone marrow transplantation using the composition. A method for enhancing the stability of a thiotepa formulation is also contemplated.
    Type: Grant
    Filed: September 1, 2022
    Date of Patent: May 7, 2024
    Assignee: SHORLA PHARMA LTD.
    Inventors: Sharon Cunningham, Orlaith Ryan, Johannes Jan Platteeuw
  • STABLE FORMULATIONS COMPRISING THIOTEPA
    Publication number: 20230041156
    Abstract: The present disclosure provides pharmaceutical compositions comprising thiotepa and one selected from PEG, such as PEG400 or PEG600, and DMSO, and optionally water or an aqueous saline solution and thiosulfate. The composition is free or substantially free of impurities. Also provided is a method for treating cancer in a subject, or myeloablation prior to bone marrow transplantation using the composition. A method for enhancing the stability of a thiotepa formulation is also contemplated.
    Type: Application
    Filed: August 29, 2022
    Publication date: February 9, 2023
    Inventors: Sharon CUNNINGHAM, Orlaith RYAN, Johannes Jan PLATTEEUW
  • STABLE FORMULATIONS COMPRISING THIOTEPA
    Publication number: 20230017521
    Abstract: The present disclosure provides pharmaceutical compositions comprising thiotepa and one selected from PEG, such as PEG400 or PEG600, and DMSO, and optionally water or an aqueous saline solution and thiosulfate. The composition is free or substantially free of impurities. Also provided is a method for treating cancer in a subject, or myeloablation prior to bone marrow transplantation using the composition. A method for enhancing the stability of a thiotepa formulation is also contemplated.
    Type: Application
    Filed: September 1, 2022
    Publication date: January 19, 2023
    Inventors: Sharon CUNNINGHAM, Orlaith RYAN, Johannes Jan PLATTEEUW